PI3 kinase activation and response to trastuzurnab therapy: What's neu with herceptin resistance?

被引：45

作者：

Park, Ben Ho ^{[1
]}

Davidson, Nancy E. ^{[1
]}

机构：

[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Breast Canc Program, Baltimore, MD 21231 USA

来源：

CANCER CELL | 2007年 / 12卷 / 04期

关键词：

D O I：

10.1016/j.ccr.2007.10.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trastuzumab is an established therapy for women with breast cancers that overexpress HER2. Despite its proven benefit in treating breast cancer, not all women derive benefit from this monoclonal antibody, and resistant disease can develop. In this issue of Cancer Cell, Berns et al. present evidence that activation of the P13 kinase pathway, either via loss of the tumor suppressor PTEN or through oncogenic stimulation of PIK3CA, can mediate trastuzumab resistance. This study extends important work of others and forms the rationale for future investigations combining inhibitors of the P13 kinase pathway in conjunction with trastuzumab therapy.

引用

页码：297 / 299

页数：3

共 10 条

[1] A transforming mutation in the pleckstrin homology domain of AKT1 in cancer [J].

Carpten, John D. ;

Faber, Andrew L. ;

Horn, Candice ;

Donoho, Gregory P. ;

Briggs, Stephen L. ;

Robbins, Christiane M. ;

Hostetter, Galen ;

Boguslawski, Sophie ;

Moses, Tracy Y. ;

Savage, Stephanie ;

Uhlik, Mark ;

Lin, Aimin ;

Du, Jian ;

Qian, Yue-Wei ;

Zeckner, Douglas J. ;

Tucker-Kellogg, Greg ;

Touchman, Jeffrey ;

Patel, Ketan ;

Mousses, Spyro ;

Bittner, Michael ;

Schevitz, Richard ;

Lai, Mei-Huei T. ;

Blanchard, Kerry L. ;

Thomas, James E. .

NATURE, 2007, 448 (7152) :439-U1

[2] Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer [J].

Henry, N. Lynn ;

Hayes, Daniel F. .

ONCOLOGIST, 2006, 11 (06) :541-552

[3] Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice [J].

Hudis, Clifford A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) :39-51

[4] Mutation of the PIK3CA oncogene in human cancers [J].

Karakas, B ;

Bachman, KE ;

Park, BH .

BRITISH JOURNAL OF CANCER, 2006, 94 (04) :455-459

[5]

Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022

[6] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J].

Romond, EH ;

Perez, EA ;

Bryant, J ;

Suman, VJ ;

Geyer, CE ;

Davidson, NE ;

Tan-Chiu, E ;

Martino, S ;

Paik, S ;

Kaufman, PA ;

Swain, SM ;

Pisansky, TM ;

Fehrenbacher, L ;

Kutteh, LA ;

Vogel, VG ;

Visscher, DW ;

Yothers, G ;

Jenkins, RB ;

Brown, AM ;

Dakhil, SR ;

Mamounas, EP ;

Lingle, WL ;

Klein, PM ;

Ingle, JN ;

Wolmark, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1673-1684

[7] 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial [J].

Smith, Ian ;

Procter, Marion ;

D Gelber, Richard ;

Guillaume, Sebastien ;

Feyereislova, Andrea ;

Dowsett, Mitch ;

Goldhirsch, Aron ;

Untch, Michael ;

Mariani, Gabriella ;

Baselga, Jose ;

Kaufmann, Manfred ;

Cameron, David ;

Bell, Richard ;

Bergh, Jonas ;

Coleman, Robert ;

Wardley, Andrew ;

Harbeck, Nadia ;

Lopez, Roberto I. ;

Mallmann, Peter ;

Gelmon, Karen ;

Wilcken, Nicholas ;

Wist, Erik ;

Sanchez Rovira, Pedro ;

Piccart-Gebhart, Martine .

LANCET, 2007, 369 (9555) :29-36

[8]

Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719

[9] American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J].

Wolff, Antonio C. ;

Hammond, M. Elizabeth H. ;

Schwartz, Jared N. ;

Hagerty, Karen L. ;

Allred, D. Craig ;

Cote, Richard J. ;

Dowsett, Mitchell ;

Fitzgibbons, Patrick L. ;

Hanna, Wedad M. ;

Langer, Amy ;

McShane, Lisa M. ;

Paik, Soonmyung ;

Pegram, Mark D. ;

Perez, Edith A. ;

Press, Michael F. ;

Rhodes, Anthony ;

Sturgeon, Catharine ;

Taube, Sheila E. ;

Tubbs, Raymond ;

Vance, Gail H. ;

de Vijver, Marc Van ;

Wheeler, Thomas M. ;

Hayes, Daniel F. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) :118-145

[10] Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers [J].

Xia, Wenle ;

Husain, Intisar ;

Liu, Leihua ;

Bacus, Sarah ;

Saini, Shermini ;

Spohn, Janice ;

Pry, Karen ;

Westlund, Ron ;

Stein, Steven H. ;

Spector, Neil L. .

CANCER RESEARCH, 2007, 67 (03) :1170-1175

← 1 →